HUTCHMED Ltd - רווח נקי למניה ב-12 החודשים האחרונים HCM

Risks for HUTCHMED (China) Limited (HCM) are linked to potential clinical trial failures and delays in the US amid high cash burn. This is offset by a biopharmaceutical ecosystem featuring its own screening system and distribution network in the PRC. Global revenue is driven by patent royalties through partnerships with industry behemoths. The rolling YoY change in earnings per share illustrates a trend where -96.00 shows the level of this metric.
HUTCHMED Corp - פילוחים אנליטיים ומדדי מפתח (HCM)

Developing innovative oncology drugs requires colossal expenditures, making the annual percentage growth chart of EPS TTM critically important for tracking the moment HUTCHMED (China) Limited (HCM) transitions to real profitability. This indicator measures the dynamics of net income per share over the last twelve months, allowing investors to objectively assess the pace of therapy monetization and the efficiency of capital management amid market volatility.